SNTI Key Statistics, Chart & Performance
The current stock price of SNTI is 2.13 USD. In the past month the price increased by 17.68%. In the past year, price decreased by -61.27%.
SNTI Latest News, Press Relases and Analysis
SNTI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About SNTI
Company Profile
Senti Biosciences, Inc. is a biotechnology company. The company is headquartered in South San Francisco, California and currently employs 34 full-time employees. The company went IPO on 2021-05-26. The firm is leveraging its synthetic biology platform to engineer gene circuits into new medicines with enhanced precision and control. These gene circuits are designed to kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. Its product candidates include SENTI-202 and SENTI-301A. SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy. SENTI-301A is a multi-armed off-the-shelf healthy donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed for the treatment of GPC3 positive tumors.
Company Info
SENTI BIOSCIENCES INC
2 Corporate Drive, First Floor
South San Francisco CALIFORNIA US
Employees: 34
Phone: 16502392030
SENTI BIOSCIENCES INC / SNTI FAQ
What does SENTI BIOSCIENCES INC do?
Senti Biosciences, Inc. is a biotechnology company. The company is headquartered in South San Francisco, California and currently employs 34 full-time employees. The company went IPO on 2021-05-26. The firm is leveraging its synthetic biology platform to engineer gene circuits into new medicines with enhanced precision and control. These gene circuits are designed to kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. Its product candidates include SENTI-202 and SENTI-301A. SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy. SENTI-301A is a multi-armed off-the-shelf healthy donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed for the treatment of GPC3 positive tumors.
Can you provide the latest stock price for SENTI BIOSCIENCES INC?
The current stock price of SNTI is 2.13 USD. The price decreased by -4.05% in the last trading session.
What is the dividend status of SENTI BIOSCIENCES INC?
SNTI does not pay a dividend.
How is the ChartMill rating for SENTI BIOSCIENCES INC?
SNTI has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the growth outlook for SENTI BIOSCIENCES INC?
The Revenue of SENTI BIOSCIENCES INC (SNTI) is expected to decline by -76.19% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for SENTI BIOSCIENCES INC?
SENTI BIOSCIENCES INC (SNTI) currently has 34 employees.
SNTI Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to SNTI. When comparing the yearly performance of all stocks, SNTI is a bad performer in the overall market: 66.76% of all stocks are doing better.
SNTI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SNTI. SNTI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SNTI Financial Highlights
Over the last trailing twelve months SNTI reported a non-GAAP Earnings per Share(EPS) of -11.54. The EPS decreased by -115.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.95% | ||
| ROE | -104.01% | ||
| Debt/Equity | 0 |
SNTI Forecast & Estimates
10 analysts have analysed SNTI and the average price target is 11.48 USD. This implies a price increase of 438.73% is expected in the next year compared to the current price of 2.13.
For the next year, analysts expect an EPS growth of 81.31% and a revenue growth -76.19% for SNTI